Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Neoplastic Disease: early-phase trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Malignant Neoplastic Disease: 2 US clinical trials tracked, none currently recruiting.
Malignant Neoplastic Disease is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Verastem, running 1 of these trials.
Enrollment posture brief
Registry condition malignant-neoplastic-disease
OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Malignant Neoplastic Disease has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Neoplastic Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Neoplastic Disease is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics
NCT03785249
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Verastem
NCT05375994
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Neoplastic Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Neoplastic Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Neoplastic Disease page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Malignant Neoplastic Disease trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Verastem sponsors the most Malignant Neoplastic Disease trials on record, review their full trial history before evaluating a specific study. See Verastem's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Neoplastic Disease condition card totals 2 registered trials; most-linked intervention avutometinib (VS-6766) and adagrasib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.